- Home
- UWMC vs ATAI Comparison
UWMC vs ATAI Comparison
Compare UWMC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UWMC | ATAI |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | UWMC | ATAI |
|---|---|---|
| Price | $1.24 | $7.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $6.13 | ★ $15.88 |
| AVG Volume (30 Days) | 10.9M | ★ 13.5M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,160,569,000.00 | $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 46.07 | ★ 1227.60 |
| 52 Week Low | $0.93 | $3.27 |
| 52 Week High | $7.09 | $7.45 |
Technical Indicators
Market Signals| Indicator | UWMC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 62.24 |
| Support Level | $0.93 | $3.32 |
| Resistance Level | $1.55 | N/A |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 50.23 |
Price Performance
Historical ComparisonAbout UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.